PROMPT:

Write a concise summary of the following:


product but for subparagraph (A). 16 (iii) SECOND 1-YEAR DELAY.If the 17 Secretary determines that there is a high 18 likelihood that such biosimilar biological 19 product will be licensed and marketed (as 20 described in clause (i)(I)) and a significant 21 amount of progress has been made by the 22 manufacturer of such biosimilar biological 23 product towards such licensure and mar24 keting (as described in clause (i)(II)), the 25 Secretary shall delay the inclusion of the bi- 109  HR 5376 EAS 1 ological product as a selected drug on the 2 list published under subsection (a) until the 3 selected drug publication date of such list 4 with respect to the initial price applica5 bility year that is 2 years after the initial 6 price applicability year for which such bio7 logical product would have been included as 8 a selected drug on such list but for this sub9 section. 10 (C) IF NOT LICENSED AND MARKETED 11 DURING THE YEAR TWO DELAY.If, during the 12 time period between the selected drug publication 13 date of the list for which the biological product 14 would have been included as a selected drug but 15 for subparagraph (B)(iii) and the selected drug 16 publication date with respect to the initial price 17 applicability year that is 2 years after the ini18 tial price applicability year for which such bio19 logical product would have been included as a se20 lected drug on such list but for this subsection, 21 the Secretary determines that such biosimilar bi22 ological product has not been licensed and mar23 keted 24 (i) the Secretary shall include such 25 biological product as a selected drug on such 110  HR 5376 EAS 1 list with respect to the initial price applica2 bility year that is 2 years after the initial 3 price applicability year for which such bio4 logical product would have been included as 5 a selected drug on such list; and 6 (ii) the manufacturer of such biologi7 cal product shall pay a rebate under para8 graph (4) with respect to the years


CONCISE SUMMARY:

==========

RESPONSE:

This section of the bill delays the inclusion of a biosimilar biological product on the list of selected drugs published under subsection (a) until the selected drug publication date of such list with respect to the initial price applicability year that is 2 years after the initial price applicability year for which such biological product would have been included as a selected drug on such list but for this subsection. If, during the time period between the selected drug publication date of the list for which the biological product would have been included as a selected drug but for this subsection and the selected drug publication date with respect to the initial price applicability year that is 2 years after the initial price applicability year for which such biological product would have been included as a selected drug on such list but for this subsection, the Secretary determines that such biosimilar biological product has not been licensed and marketed, the Secretary shall include such biological product as a selected drug on such list with respect to the initial price applicability year that is 2 years after the initial price applicability year for which such biological product would have been included as a selected drug on such list.